ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,061,706 | +53.6% | 2,103,780 | +117.9% | 0.00% | – |
| Q2 2023 | $1,341,936 | -40.5% | 965,421 | -32.0% | 0.00% | – |
| Q1 2023 | $2,256,245 | -79.7% | 1,419,022 | -20.6% | 0.00% | -100.0% |
| Q4 2022 | $11,128,170 | +64.5% | 1,786,223 | +76.9% | 0.00% | 0.0% |
| Q3 2022 | $6,766,000 | +33.9% | 1,009,781 | +27.1% | 0.00% | 0.0% |
| Q2 2022 | $5,054,000 | +193.7% | 794,711 | +114.2% | 0.00% | – |
| Q1 2022 | $1,721,000 | -22.7% | 370,991 | -16.7% | 0.00% | – |
| Q4 2021 | $2,226,000 | -59.1% | 445,212 | -1.5% | 0.00% | -100.0% |
| Q3 2021 | $5,444,000 | -33.4% | 451,824 | +16.9% | 0.00% | 0.0% |
| Q2 2021 | $8,175,000 | +170.7% | 386,515 | +258.9% | 0.00% | – |
| Q1 2021 | $3,020,000 | -50.7% | 107,702 | -54.2% | 0.00% | -100.0% |
| Q4 2020 | $6,122,000 | +373.1% | 235,411 | +575.7% | 0.00% | – |
| Q3 2020 | $1,294,000 | -49.3% | 34,838 | -30.0% | 0.00% | -100.0% |
| Q2 2020 | $2,551,000 | +306.9% | 49,739 | +150.2% | 0.00% | – |
| Q1 2020 | $627,000 | -82.2% | 19,882 | -66.3% | 0.00% | -100.0% |
| Q4 2019 | $3,522,000 | +362.8% | 59,051 | +184.2% | 0.00% | – |
| Q3 2019 | $761,000 | -81.1% | 20,776 | -76.0% | 0.00% | -100.0% |
| Q2 2019 | $4,027,000 | +76.2% | 86,553 | +52.1% | 0.00% | 0.0% |
| Q1 2019 | $2,286,000 | -74.8% | 56,924 | -71.1% | 0.00% | -66.7% |
| Q4 2018 | $9,057,000 | +184.8% | 196,890 | +174.6% | 0.00% | +200.0% |
| Q3 2018 | $3,180,000 | +2.7% | 71,700 | -9.3% | 0.00% | 0.0% |
| Q2 2018 | $3,097,000 | -38.2% | 79,023 | +14.1% | 0.00% | 0.0% |
| Q1 2018 | $5,010,000 | -6.8% | 69,258 | -15.2% | 0.00% | 0.0% |
| Q4 2017 | $5,377,000 | +223.1% | 81,674 | +145.9% | 0.00% | – |
| Q3 2017 | $1,664,000 | -18.9% | 33,212 | -25.1% | 0.00% | -100.0% |
| Q2 2017 | $2,052,000 | -62.5% | 44,341 | -71.4% | 0.00% | 0.0% |
| Q1 2017 | $5,474,000 | +172.9% | 155,078 | -3.2% | 0.00% | – |
| Q4 2016 | $2,006,000 | +195.0% | 160,172 | +226.2% | 0.00% | – |
| Q3 2016 | $680,000 | -45.6% | 49,102 | -61.2% | 0.00% | – |
| Q2 2016 | $1,250,000 | +176.5% | 126,530 | +374.2% | 0.00% | – |
| Q1 2016 | $452,000 | -35.8% | 26,682 | -15.5% | 0.00% | – |
| Q4 2015 | $704,000 | -15.9% | 31,589 | -11.1% | 0.00% | – |
| Q3 2015 | $837,000 | -87.2% | 35,524 | -55.5% | 0.00% | -100.0% |
| Q2 2015 | $6,527,000 | +35.6% | 79,835 | +53.6% | 0.00% | 0.0% |
| Q1 2015 | $4,813,000 | +19.0% | 51,971 | -48.0% | 0.00% | +100.0% |
| Q4 2014 | $4,044,000 | +15.6% | 99,984 | -30.1% | 0.00% | 0.0% |
| Q3 2014 | $3,497,000 | +40.3% | 142,949 | -9.2% | 0.00% | 0.0% |
| Q2 2014 | $2,493,000 | -1.5% | 157,374 | -6.0% | 0.00% | 0.0% |
| Q1 2014 | $2,532,000 | +327.0% | 167,484 | +288.3% | 0.00% | – |
| Q4 2013 | $593,000 | -83.7% | 43,133 | -77.6% | 0.00% | -100.0% |
| Q3 2013 | $3,631,000 | – | 192,541 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |